{
    "id": "correct_subsidiary_00126_2",
    "rank": 23,
    "data": {
        "url": "https://www.novonordisk-us.com/",
        "read_more_link": "",
        "language": "en",
        "title": "Welcome to Novo Nordisk in the U.S.",
        "top_image": "https://www.novonordisk-us.com/content/dam/nncorp/us/en_us/homepage/images/sheenia-chandler-sickle-cell-disease-area.jpg",
        "meta_img": "https://www.novonordisk-us.com/content/dam/nncorp/us/en_us/homepage/images/sheenia-chandler-sickle-cell-disease-area.jpg",
        "images": [],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Learn all about Novo Nordisk in the U.S. and how we're helping to defeat diabetes, rare bleeding disorders, growth hormone-related disorders, and obesity.",
        "meta_lang": "en",
        "meta_favicon": "/etc.clientlibs/nncorp/components/structure/page/clientlib/resources/favicon.ico",
        "meta_site_name": "Novo Nordisk",
        "canonical_link": "https://www.novonordisk-us.com/",
        "text": "Ozempic® (semaglutide) injection 1 mg demonstrated reduction in risk of kidney disease-related events in Phase 3 FLOW trial presented at the 84th Scientific Sessions of the American Diabetes Association\n\nHere are our current job openings. If we don’t currently have an opening in your area of interest, we encourage you to create a job agent and candidate profile."
    }
}